GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

Cytoreductive surgery, whether performed as the initial treatment or following neoadjuvant chemotherapy (NACT) for advanced ...

BAT-8006 is under clinical development by Bio-Thera Solutions and currently in Phase II for Epithelial Ovarian Cancer.

Epithelial ovarian cancer is the fourth biggest cause of cancer-related death in women. Over recent decades, improvements have been made in treatment outcome in terms of response rate and survival.

among subjects with breast cancer gene (BRCA) non-mutated advanced epithelial ovarian cancer. The randomised, double-blind trial's primary endpoints focused on progression-free survival (PFS ...

A phase 1 trial evaluating FSHR-targeting CAR T cells for patients with ovarian cancer has dosed the first patient in its ...

Caribbean and African regions report a lower incidence of ovarian cancer. This highly heterogeneous malignancy has multiple histological subtypes. Epithelial ovarian cancers account for 90% of all ...

Between 1988 and 2017, there were significant global variations and trends in ovarian cancer incidence and its subtypes, ...

Potential practice-changing therapies in gynecologic cancer include the emergence of carboplatin, paclitaxel, and PD-1 ...

Specifically, Elahere (mirvetuximab soravtansine) can be used in adults with platinum-resistant, FRα-expressing high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer ...